An Industry Overview
Nigeria’s pharmaceutical sector is going through a genuine structural reset. Some multinational pharmaceutical firms such as GlaxoSmithKline (GSK), Sanofi Nigeria and a few others have left the country, citing increased operational cost, forex scarcity, naira devaluation, and the economic impact. Drug prices have climbed faster than incomes for three consecutive years, and yet, local manufacturers posted a 127% jump in profit in the first nine months of 2025.
The Backstory: 2020–2024
Between 2020 and 2024, twelve multinational pharmaceutical companies exited Nigeria. The most consequential departures were GlaxoSmithKline in August 2023, ending 51 years of operations, and Sanofi-Aventis in 2024. Pfizer had already wound down direct operations earlier. These were not marginal players. They defined market standards, anchored hospital procurement decisions, and between them covered vaccines, oncology, infectious disease, and chronic care.
Their stated reasons were consistent; FX volatility made it impossible to repatriate profits, the naira’s depreciation compressed the dollar value of naira-denominated revenues, and they could not reliably source foreign currency to import raw materials. One PMC study was direct about it, the high exchange rate of the naira to foreign currencies was “the greatest contributor” to these companies’ financial difficulties in Nigeria.
The immediate consequences were predictable. Drug prices for some products reportedly surged by as much as 1,000% following GSK’s exit, a survey of 50 pharmacies found that 94% of respondents believed the exits had directly caused drug shortages. The three healthcare practitioners who wrote to The Lancet about the departures warned of supply chain breakdown and a resurgence of preventable disease.
Where the Industry Stands Today
Nigeria’s pharmaceutical market was estimated at roughly $1.4 billion a few years ago. By Statista’s projections, it crossed $1.84 billion in 2025 and is tracking toward $2.36 billion by 2029, at a compound annual growth rate of about 6.45%. Population growth, rising disease burden, and the expansion of the National Health Insurance Authority (NHIA) are driving demand, regardless of what is happening on the supply or cost side.
But the operating environment tells a different story from the revenue trajectory. The industry is simultaneously growing and struggling, and understanding why requires looking at three interlocking pressures: who left, what it costs to borrow, and what FX volatility has done to every cost line.
FX Exposure: The Permanent Problem
Over 70% of finished drugs and active pharmaceutical ingredients used in Nigeria are imported, primarily from India and China. Even locally manufactured products rely heavily on imported APIs and excipients. This means that every movement in the naira-to-dollar exchange rate flows directly into the cost of goods.
The exchange rate trajectory over five years:
| Year | Approximate Official Rate | Notes |
| 2021 | 410 | Multiple exchange rate windows in operation |
| 2022 | 430 | Continued CBN administrative management |
| 2023 (pre-reform) | 460 | Artificial stability masking structural pressure |
| 2023 (post-reform | 900–1,000 | FX unification, naira devaluation |
| 2024 | 1,500–1,540 | Peak volatility, multinational exits accelerate |
| 2025 | 1,430–1,520 | Stabilisation, first annual appreciation since 2012 |
| 2026 (YTD) | 1,350–1,390 | Further naira gains amid CBN reforms |
What this table cannot fully capture is the volatility within years. In 2024, the average exchange rate was approximately ₦1,486/$, but intra-year swings were wide and unpredictable, making procurement planning nearly impossible for any business buying in dollars and selling in naira.
For a pharmaceutical company, the working capital implication is direct. If it takes 90 days from purchase order to sale, and the naira depreciates 10% during that window, the company’s margin disappears before a tablet reaches a patient. Even with the relative stability of 2025–2026, the exchange rate today is still roughly three times what it was before the 2023 reforms. A company carrying inventory valued at 2021 exchange rates against 2026 payables is living in a permanent mismatch.
Nigeria’s new tax framework adds a technical layer: under Section 20(4) of the Nigeria Tax Act 2025, foreign currency expenses are deductible only at the official CBN rate. Any premium paid in unofficial channels to secure dollars faster cannot be deducted. This essentially penalises companies that have no choice but to source FX outside the official window.
Health Inflation: The Human Consequence
The numbers at the population level are stark. Nigeria’s headline inflation eased to 15.06% in February 2026. Health sector inflation came in at 28.62% for the same month, nearly double the headline rate, and up from 19.58% in February 2025.
Prescription medication costs increased by an average of 22% annually between 2020 and 2025. A basic malaria treatment course can cost ₦7,000, roughly 9% of the minimum monthly wage of ₦77,000. For patients managing chronic conditions, hypertension, diabetes, HIV, the arithmetic is unsustainable.
The FX Reality Today: Stability Without Accessibility
The narrative around Nigeria’s foreign exchange market has shifted slightly in 2025 and early 2026. On paper, the naira has shown signs of relative stability compared to the extreme volatility of 2023–2024. Policy reforms by the Central Bank have improved price discovery, narrowed arbitrage gaps, and restored a level of confidence among foreign investors.
But for businesses, especially in the pharmaceutical sector, stability has not translated into accessibility.
Access to foreign exchange remains inconsistent, fragmented, and often delayed. Official channels are still unable to meet the full demand for dollars, particularly for import-dependent industries like pharmaceuticals. Companies are forced into difficult trade-offs: wait for official allocation and risk stockouts, or source FX from alternative channels at a premium and absorb the cost impact. Either path erodes margins, disrupts planning cycles, and introduces uncertainty into already fragile supply chains.
For pharmaceutical companies operating on tight inventory cycles and critical delivery timelines, this is not just a financial problem; it is an operational risk with real human consequences.
Closing the Gap: How Bluebulb is Rewiring Cross-Border Payments
This is where infrastructure, not policy, becomes the differentiator.
Bluebulb is addressing one of the most critical gaps in the system: the ability for African businesses to access, move, and settle foreign currency transactions with speed, transparency, and predictability. Instead of navigating fragmented FX channels or dealing with prolonged settlement timelines, pharmaceutical companies can execute cross-border payments seamlessly, ensuring suppliers are paid on time and inventory flows remain uninterrupted.
Take Control of Your FX Operations
In a market where timing and access to foreign currency can determine whether a shipment moves or stalls, businesses need more than fragmented solutions, they need reliability built into their payment infrastructure.
That’s where Orbita by Bluebulb comes in.
Designed to support African businesses navigating complex cross-border payment and FX challenges, Orbita helps pharmaceutical companies and import-dependent sectors simplify how they access and move foreign currency. From reducing settlement delays to improving payment predictability, Orbita gives businesses a more stable way to manage international obligations in an unstable FX environment.
Sign up on Orbita today for self-service or contact the team today for tailored support for your business.
Leave a Reply